Chronic treatment with Carvedilol improves ventricular function and reducesmyocyte apoptosis in an animal model of heart failure
Authors:
- Chukwuka C OkaforCOChukwuka C Okafor
- Cynthia Perreault-MicaleCPCynthia Perreault-Micale
- Roger J HajjarRHRoger J Hajjar
- Djamel LebecheDLDjamel Lebeche
- Klara SkiromanKSKlara Skiroman
- George JabbourGJGeorge Jabbour
- Angelia A DoyeADAngelia A Doye
- Michael X LeeMLMichael X Lee
- Nancy LasteNLNancy Laste
- Judith K GwathmeyJGJudith K Gwathmey
Open Access
- 21 July 2003
- journal article
- Published by Springer Nature in BMC Physiology
- Vol. 3 (1) , 6
Abstract
Beta blocker treatment has emerged as an effective treatment modality for heart failure. Interestingly, beta-blockers can activate both pro-apoptotic and anti-apoptotic pathways. Nevertheless, the mechanism for improved cardiac function seen with beta-blocker treatment remains largely unknown. Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties. We therefore studied the impact of the effects of carvedilol in an animal model of end-stage heart failure. To test whether chronic treatment with beta-blockade decreases apoptosis, we treated myopathic turkeys with two dosages of carvedilol, 1 mg/kg (DCM1) and 20 mg/kg (DCM20), for four weeks and compared them to non-treated DCM animals (DCM0) and to control turkeys (CON). Echocardiographic measurements showed that non-treated DCM animals had a significantly lower fractional shortening (FS) when compared to CON (68.73 +/- 1.37 vs. 18.76 +/- 0.59%, p < 0.001). Both doses of carvedilol significantly improved FS (33.83 +/- 10.11 and 27.73 +/- 6.18% vs. 18.76 +/- 0.59% for untreated DCM, p < 0.001). DCM left ventricles were characterized by a higher percentage of apoptotic nuclei when compared to CON (5.64 +/- 0.49 vs. 1.72 +/- 0.12%, respectively p < 0.001). Both doses of carvedilol significantly reduced the number of apoptotic nuclei (2.32 +/- 0.23% and 2.36 +/-6% 1 mg and 20 mg/kg respectively). Carvedilol improves ventricular function. Furthermore, treatment with carvedilol decreased the incidence of apoptosis in cardiac myocytes from failing hearts at both doses. These data suggest that the inhibition of apoptosis with carvedilol may lead to improvement in ventricular function and may underlie a beneficial effect of beta-blockade independent of heart rate lowering effects.Keywords
This publication has 38 references indexed in Scilit:
- Adrenergic regulation of cardiac myocyte apoptosisJournal of Cellular Physiology, 2001
- Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell.Journal of Clinical Investigation, 1998
- Angiotensin II Induces Apoptosis of Adult Ventricular MyocytesIn VitroJournal of Molecular and Cellular Cardiology, 1997
- Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death.Journal of Clinical Investigation, 1996
- Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathyThe American Journal of Cardiology, 1996
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized studyJACC, 1995
- Beta-blockers in heart failure: Promising or proved?JACC, 1994
- Oxidative stress as a mediator of apoptosisImmunology Today, 1994
- Pathophysiological and biochemical characterisation of an avian model of dilated cardiomyopathy: comparison to findings in human dilated cardiomyopathyCardiovascular Research, 1993